Terms: = Prostate cancer AND ZRSR2, URP, 8233, ENSG00000169249, U2AF1RS2, MGC142040, U2AF1L2, U2AF1-RS2, MGC142014
3 results:
1. zrsr2 overexpression is a frequent and early event in castration-resistant prostate cancer development.
He H; Hao J; Dong X; Wang Y; Xue H; Qu S; Choi SYC; Ci X; Wang Y; Wu R; Shi M; Zhao X; Collins C; Lin D; Wang Y
Prostate Cancer Prostatic Dis; 2021 Sep; 24(3):775-785. PubMed ID: 33568749
[TBL] [Abstract] [Full Text] [Related]
2. [Quantitative detection of differential display code 3 mRNA in peripheral blood of patients with prostate cancer].
Weng ZL; Yu KY; Mao XL; Tao ZH; Chen XD; Wu XL; Hu YP; Wang SQ; Li CD; Chen ZG
Zhonghua Yi Xue Za Zhi; 2006 Nov; 86(41):2911-5. PubMed ID: 17288789
[TBL] [Abstract] [Full Text] [Related]
3. High-dose-rate brachytherapy as monotherapy for localized prostate cancer: a retrospective analysis with special focus on tolerance and chronic toxicity.
Yoshioka Y; Nose T; Yoshida K; Oh RJ; Yamada Y; Tanaka E; Yamazaki H; Inoue T; Inoue T
Int J Radiat Oncol Biol Phys; 2003 May; 56(1):213-20. PubMed ID: 12694841
[TBL] [Abstract] [Full Text] [Related]
